NPPA fixes retail prices of 44 formulations
National Pharmaceutical Pricing Authority (NPPA) has fixed retail prices of 44 formulations including those indicated for the treatment of hypertension, depression, high blood sugar levels caused by type 2 diabetes, etc under Drugs (Prices Control) Order, 2013.
The price fixation is based on the decision of 115th Authority meeting dated 31.07.2023.
The drugs whose prices have been fixed include MSN Labs and Sanofi India's Sitagliptin Phosphate and Metformin Hydrochloride Tablets, Akum Drugs & Pharma and Mankind Pharma's Levetiracetam, Sodium Chloride Infusion, Akums Drugs & Pharma and Abbott Healthcare's Aceclofeanc, Paracetamol & Serratiopeptidase Tablet, Akums Drugs & Pharma and Cipla's Chlorthalidone, Amlodipine & Telmisartan Tablets.
For more details, check out the link given below:
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.